Health Care
Sonora Behavioral Health
RN General
Acorn
Activist/Organizer Mechanical
Pioneer Landscaping
Diesel Fleet Mechanics Office and Clerical
Pima County Fair
Front Desk Receptionist Finance and Accounting
VALOR HOSPICE CARE
CONTROLLER General
Award Service Inc
Route Sales Health Care
RLM Services, Inc.
Pharmacist

WASHINGTON — A drug similar to one that causes birth defects has won FDA approval to treat anemia in people who suffer from certain kinds of rare bone-marrow disorders known as myelodysplastic syndromes, or MDS.

The Food and Drug Administration approved the drug, lenalidomide, late Tuesday. Celgene Corp., of Summit, N.J., plans to market the drug as Revlimid.

The drug is similar to thalidomide, known to cause birth defects.

The company must market Revlimid under a risk management plan to keep it from being used by women who may become pregnant. Female patients must undergo pregnancy testing and give informed consent before they can take the drug, which will bear a so-called "black box warning" on its label. Pharmacists and others who prescribe and dispense the drug must register with the risk management program, the FDA said.

MDS refers to various disorders caused when bone marrow does not make enough normal blood cells. Patients with MDS can require blood and platelet transfusions and treatment with antibiotics for infections.

Patients treated with Revlimid in clinical trials went transfusion-free for 44 weeks on average, according to the FDA.

About 7,000 to 12,000 new cases of MDS are diagnosed each year in the United States. Symptoms include weakness, fatigue, infections, bruising, bleeding and fever.

"This new product will offer a much needed treatment option for patients suffering from this rare illness that, in some cases, has been found to progress to fatal forms of leukemia," said Dr. Steven Galson, director of FDA's Center for Drug Evaluation and Research.

The drug's warning also includes the potential need to lower the common dose because of suppressed blood counts and increased risk of blood clots in patients, the FDA said.